Christian Veltmann

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1238555/publications.pdf

Version: 2024-02-01

107	4,714	76196	102304
papers	citations	40	66
		h-index	g-index

126	126	126	4343
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Stereotactic radioablation for ventricular tachycardia. Herzschrittmachertherapie Und Elektrophysiologie, 2022, 33, 49-54.	0.3	5
2	Delayed Improvement of Left Ventricular Function in Newly Diagnosed Heart Failure Depends on Etiologyâ€”A PROLONG-II Substudy. Sensors, 2022, 22, 2037.	2.1	3
3	Usage of the wearable cardioverter-defibrillator during pregnancy. IJC Heart and Vasculature, 2022, 41, 101066.	0.6	1
4	Reduction of inappropriate implantable cardioverter-defibrillator therapies using enhanced supraventricular tachycardia discriminators: the ReduceIT study. Journal of Interventional Cardiac Electrophysiology, 2021, 61, 339-348.	0.6	4
5	Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry. Clinical Research in Cardiology, 2021, 110, 102-113.	1.5	13
6	Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part 2: ventricular arrhythmias, channelopathies, and implantable defibrillators. Europace, 2021, 23, 147-148.	0.7	47
7	Eligibility for subcutaneous implantable cardioverter-defibrillator in patients with left ventricular assist device. Journal of Interventional Cardiac Electrophysiology, 2021, 60, 303-311.	0.6	7
8	Comparison of transvenous vs subcutaneous defibrillator therapy in patients with cardiac arrhythmia syndromes and genetic cardiomyopathies. International Journal of Cardiology, 2021, 323, 100-105.	0.8	13
9	A Primary Prevention Clinical Risk Score Model for Patients With Brugada Syndrome (BRUGADA-RISK). JACC: Clinical Electrophysiology, 2021, 7, 210-222.	1.3	50
10	Eligibility for subcutaneous implantable cardioverterâ€defibrillator in adults with congenital heart disease. ESC Heart Failure, 2021, 8, 1502-1508.	1.4	13
11	ECG and arrhythmias in peripartum cardiomyopathy. Herzschrittmachertherapie Und Elektrophysiologie, 2021, 32, 207-213.	0.3	3
12	Smart Wearables for Cardiac Monitoringâ€”Real-World Use beyond Atrial Fibrillation. Sensors, 2021, 21, 2539.	2.1	63
13	RELATION OF HEART RATE AND BETA BLOCKER OR IVABRADINE USE IN PATIENTS WITH NEWLY DIAGNOSED HEART FAILURE WITH REDUCED LVEF. Journal of the American College of Cardiology, 2021, 77, 733.	1.2	0
14	Author reply: Sâ€ICD eligibilities in adults with congenital heart disease. ESC Heart Failure, 2021, 8, 3444-3446.	1.4	1
15	A Novel SCN5A Variant Causes Temperature-Sensitive Loss Of Function in a Family with Symptomatic Brugada Syndrome, Cardiac Conduction Disease, and Sick Sinus Syndrome. Cardiology, 2021, 146, 754-762.	0.6	2
16	Leadless pacemakers in critically ill patients requiring prolonged cardiac pacing: A multicenter international study. Journal of Cardiovascular Electrophysiology, 2021, 32, 2522-2527.	0.8	3
17	Premature end of service of implantable cardioverter-defibrillator by magnetic interference with left-ventricular assist device. HeartRhythm Case Reports, 2021, 7, 691-693.	0.2	1
18	Genotype-Phenotype Correlation of SCN5A Genotype in Patients With Brugada Syndrome and Arrhythmic Events: Insights From the SABRUS in 392 Probands. Circulation Genomic and Precision Medicine, 2021, 14, e003222.	1.6	7

#	Article	IF	Citations
19	Extended followâ€up after wearable cardioverterâ€defibrillator period: the PROLONGâ€II study. ESC Heart Failure, 2021, 8, 5142-5148.	1.4	12
20	Feasibility and First Results of Heart Failure Monitoring Using the Wearable Cardioverterâ€"Defibrillator in Newly Diagnosed Heart Failure with Reduced Ejection Fraction. Sensors, 2021, 21, 7798.	2.1	6
21	Heart rate control in heart failure with reduced ejection fraction: the bright and the dark side of the moon. European Journal of Heart Failure, 2020, 22, 539-542.	2.9	7
22	A novel screening tool to unmask potential interference between Sâ€ICD and left ventricular assist device. Journal of Cardiovascular Electrophysiology, 2020, 31, 3286-3292.	0.8	8
23	One-Year Course of Periprocedural Anticoagulation in Atrial Fibrillation Ablation: Results of a German Nationwide Survey. Cardiology, 2020, 145, 676-681.	0.6	4
24	SCN5A Mutation Type and a Genetic Risk Score Associate Variably With Brugada Syndrome Phenotype in SCN5A Families. Circulation Genomic and Precision Medicine, 2020, 13, e002911.	1.6	41
25	A novel openâ€source softwareâ€based highâ€precision workflow for target definition in cardiac radioablation. Journal of Cardiovascular Electrophysiology, 2020, 31, 2689-2695.	0.8	28
26	Autophagy alleviates amiodarone-induced hepatotoxicity. Archives of Toxicology, 2020, 94, 3527-3539.	1.9	13
27	Continued misuse of orphan drug legislation: a life-threatening risk for mexiletine. European Heart Journal, 2020, 41, 614-617.	1.0	15
28	Defibrillators for prevention from sudden cardiac death: is it that easy?. Europace, 2020, 22, 1298-1298.	0.7	0
29	When two hearts do not beat as one â€" An unusual cause of pacemaker related tachycardia. Journal of Electrocardiology, 2019, 57, 6-9.	0.4	0
30	Ethnic differences in patients with Brugada syndrome and arrhythmic events: New insights from Survey on Arrhythmic Events in Brugada Syndrome. Heart Rhythm, 2019, 16, 1468-1474.	0.3	22
31	Longâ€term followâ€up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery, but significant cardiovascular coâ€morbidities. European Journal of Heart Failure, 2019, 21, 1534-1542.	2.9	51
32	Initial experience with telemonitoring in left ventricular assist device patients. Journal of Thoracic Disease, 2019, 11, S853-S863.	0.6	25
33	Rationale and design of the DIGITâ€HF trial (DIGitoxin to Improve ouTcomes in patients with advanced) Tj ETQq1 1 0.784314 rgBT /O Heart Failure, 2019, 21, 676-684.	2.9	51
34	Characterization and Management of Arrhythmic Events in Young Patients With Brugada Syndrome. Journal of the American College of Cardiology, 2019, 73, 1756-1765.	1.2	53
35	Time-to-first appropriate shock in patients implanted prophylactically with an implantable cardioverter-defibrillator: data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS). Europace, 2019, 21, 796-802.	0.7	16
36	Electrocardiographic changes after implantation of a left ventricular assist device â€" Potential implications for subcutaneous defibrillator therapy. Journal of Electrocardiology, 2019, 52, 29-34.	0.4	10

#	Article	IF	Citations
37	Fever-related arrhythmic events in the multicenter Survey on Arrhythmic Events in Brugada Syndrome. Heart Rhythm, 2018, 15, 1394-1401.	0.3	71
38	Profile of patients with Brugada syndrome presenting with their first documented arrhythmic event: Data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS). Heart Rhythm, 2018, 15, 716-724.	0.3	57
39	Implantable cardioverter defibrillator therapy in grown-up patients with transposition of the great arteriesâ€"role of anti-tachycardia pacing. Journal of Thoracic Disease, 2018, 10, S1769-S1776.	0.6	3
40	Role of the Wearable Defibrillator in Newly Diagnosed Heart Failure. Current Heart Failure Reports, 2018, 15, 368-375.	1.3	12
41	Cardiac pacemaker channel (HCN4) inhibition and atrial arrhythmogenesis after releasing cardiac sympathetic activation. Scientific Reports, 2018, 8, 7748.	1.6	6
42	Gender differences in patients with Brugada syndrome and arrhythmic events: Data from a survey on arrhythmic events in 678 patients. Heart Rhythm, 2018, 15, 1457-1465.	0.3	65
43	Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillatorâ€"The PROLONG Study. Journal of the American Heart Association, 2017, 6, .	1.6	67
44	Electric smog: telemetry interference between ICD and LVAD. Herzschrittmachertherapie Und Elektrophysiologie, 2017, 28, 257-259.	0.3	18
45	Systematic ajmaline challenge in patients with long QT 3 syndrome caused by the most common mutation: a multicentre study. Europace, 2017, 19, 1723-1729.	0.7	10
46	Ventricular arrhythmias in patients with newly diagnosed nonischemic cardiomyopathy: Insights from the <scp>PROLONG</scp> study. Clinical Cardiology, 2017, 40, 586-590.	0.7	26
47	Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy with low ejection fraction: a German multi-centre analysis. Clinical Research in Cardiology, 2017, 106, 582-589.	1.5	67
48	Optimizing Antitachycardia Pacing. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	2.1	6
49	Age of First Arrhythmic Event in Brugada Syndrome. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	2.1	57
50	One symptom, two arrhythmias: the rare and the even rarer. BMC Cardiovascular Disorders, 2017, 17, 244.	0.7	0
51	The â€œPain waveâ€• Pâ€‘wave oversensing in subcutaneous ICD. Herzschrittmachertherapie Und Elektrophysiologie, 2016, 27, 151-153.	0.3	0
52	Subcutaneous Implantable Cardioverter-Defibrillator Shocks After Left Ventricular Assist Device Implantation. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	2.1	34
53	Further Insights in the Most Common SCN5A Mutation Causing Overlapping Phenotype of Long QT Syndrome, Brugada Syndrome, and Conduction Defect. Journal of the American Heart Association, 2016, 5, .	1.6	46
54	Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure, 2016, 18, 1096-1105.	2.9	160

#	Article	IF	Citations
55	Early repolarization pattern: a marker of increased risk in patients with catecholaminergic polymorphic ventricular tachycardia. Europace, 2016, 18, 1587-1592.	0.7	16
56	Brugada syndrome: clinical presentation and genotypeâ€"correlation with magnetic resonance imaging parameters. Europace, 2016, 18, 1411-1419.	0.7	40
57	The Wearable Cardioverter/Defibrillator - Toy Or Tool?. Journal of Atrial Fibrillation, 2016, 8, 1367.	0.5	14
58	Idiopathic Ventricular Fibrillation. , 2014, , 967-973.		1
59	Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular functionâ€"value of the wearable cardioverter/defibrillator. European Journal of Heart Failure, 2014, 16, 1331-1336.	2.9	121
60	ABCC9 is a novel Brugada and early repolarization syndrome susceptibility gene. International Journal of Cardiology, 2014, 171, 431-442.	0.8	113
61	Mutations in SCN10A Are Responsible for a Large Fraction of Cases of Brugada Syndrome. Journal of the American College of Cardiology, 2014, 64, 66-79.	1.2	212
62	PQ segment depression in patients with short QT syndrome: A novel marker for diagnosing short QT syndrome?. Heart Rhythm, 2014, 11, 1024-1030.	0.3	28
63	Reply to the Editorâ€"PQ-Segment Depression in Short QT Syndrome Patients: A Novel Marker for Diagnosing Short QT Syndrome?. Heart Rhythm, 2014, 11, e8.	0.3	1
64	163â€...Genetic Modifiers in Carriers of the SCN5A E1784K Mutation with Variable Phenotypic Expression - Long QT3 / Brugada Syndrome Overlap Disease. Heart, 2014, 100, A94.1-A94.	1.2	0
65	Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm, 2013, 10, 542-547.	0.3	88
66	Impact of Shocks on Mortality in Patients with Ischemic or Dilated Cardiomyopathy and Defibrillators Implanted for Primary Prevention. PLoS ONE, 2013, 8, e63911.	1.1	19
67	A novel rare variant in SCN1Bb linked to Brugada syndrome and SIDS by combined modulation of Na 1.5 and K 4.3 channel currents. Heart Rhythm, 2012, 9, 760-769.	0.3	104
68	Early repolarization pattern is associated with ventricular fibrillation in patients with acute myocardial infarction. Heart Rhythm, 2012, 9, 1295-1300.	0.3	83
69	Molecular genetic and functional association of Brugada and early repolarization syndromes with S422L missense mutation in KCNJ8. Heart Rhythm, 2012, 9, 548-555.	0.3	152
70	Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide. Heart Rhythm, 2012, 9, 776-781.	0.3	52
71	Short QT Syndrome. , 2011, , 189-196.		0
72	Comparison of Ventricular Tachyarrhythmia Characteristics in Patients With Idiopathic Dilated or Ischemic Cardiomyopathy and Defibrillators Implanted for Primary Prevention. Clinical Cardiology, 2011, 34, 604-609.	0.7	25

#	Article	IF	Citations
73	A 'Schwartz score' for short QT syndrome. Nature Reviews Cardiology, 2011, 8, 251-252.	6.1	11
74	Predictors of electrical storm recurrences in patients with implantable cardioverter-defibrillators. Europace, 2011, 13, 668-674.	0.7	34
75	Prevention of inappropriate ICD shocks in patients with Brugada syndrome. Clinical Research in Cardiology, 2010, 99, 37-44.	1.5	49
76	Extent of late gadolinium enhancement detected by cardiovascular magnetic resonance correlates with the inducibility of ventricular tachyarrhythmia in hypertrophic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2010, 12, 30.	1.6	74
77	Spontaneous type 1 electrocardiographic pattern is associated with cardiovascular magnetic resonance imaging changes in Brugada syndrome. Heart Rhythm, 2010, 7, 1790-1796.	0.3	42
78	Mutation in Nav1.5 Associated with Brugada Syndrome - a Mutational Hotspot?. Biophysical Journal, 2010, 98, 311a.	0.2	1
79	Cryoablation Versus Radiofrequency Energy for the Ablation of Atrioventricular Nodal Reentrant Tachycardia (the CYRANO Study). Circulation, 2010, 122, 2239-2245.	1.6	150
80	Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. Heart Rhythm, 2010, 7, 1872-1882.	0.3	387
81	Overlapping LQT1 and LQT2 phenotype in a patient with long QT syndrome associated with loss-of-function variations in KCNQ1 and KCNH2. Canadian Journal of Physiology and Pharmacology, 2010, 88, 1181-1190.	0.7	12
82	Short QT Syndrome. , 2010, , 149-156.		0
83	Yew Causes Brugada ECG. Circulation, 2009, 119, 1836-1837.	1.6	12
84	Response to intravenous ajmaline: a retrospective analysis of 677 ajmaline challenges. Europace, 2009, 11, 1345-1352.	0.7	64
85	Channelopathies: Brugada syndrome, long QT syndrome, short QT syndrome, and CPVT. Herz, 2009, 34, 281-288.	0.4	50
86	Risk Stratification in Electrical Cardiomyopathies. Herz, 2009, 34, 518-527.	0.4	8
87	Variability of the Diagnostic ECG Pattern in an ICD Patient Population with Brugada Syndrome. Journal of Cardiovascular Electrophysiology, 2009, 20, 69-75.	0.8	74
88	Role of proinflammatory markers and NT-proBNP in patients with an implantable cardioverter-defibrillator and an electrical storm. Cytokine, 2009, 47, 166-172.	1.4	42
89	Are Women with Severely Symptomatic Brugada Syndrome Different from Men?. Journal of Cardiovascular Electrophysiology, 2008, 19, 1181-1185.	0.8	41
90	Prevalence of Supraventricular Tachyarrhythmias in a Cohort of 115 Patients with Brugada Syndrome. Annals of Noninvasive Electrocardiology, 2008, 13, 266-269.	0.5	46

#	Article	IF	Citations
91	Electromechanical coupling in patients with the short QT syndrome: Further insights into the mechanoelectrical hypothesis of the U wave. Heart Rhythm, 2008, 5, 241-245.	0.3	61
92	Is a narrow and tall QRS complex an ECG marker for sudden death?. Heart Rhythm, 2008, 5, 1339-1345.	0.3	24
93	To the Editor Response. Heart Rhythm, 2008, 5, 1091-1092.	0.3	1
94	Clinical Aspects and Prognosis of Brugada Syndrome in Children. Circulation, 2007, 115, 2042-2048.	1.6	275
95	Prospective study of interleukin-6 and the risk of malignant ventricular tachyarrhythmia in ICD-recipientsâ€"A pilot study. Cytokine, 2007, 40, 30-34.	1.4	39
96	Fatal Inappropriate ICD Shock. Journal of Cardiovascular Electrophysiology, 2007, 18, 326-328.	0.8	47
97	In vivo Effects of Mutant HERG K+Channel Inhibition by Disopyramide in Patients with a Short QT-1 Syndrome: A Pilot Study. Journal of Cardiovascular Electrophysiology, 2007, 18, 1157-1160.	0.8	62
98	A prospective study on spontaneous fluctuations between diagnostic and non-diagnostic ECGs in Brugada syndrome: implications for correct phenotyping and risk stratification. European Heart Journal, 2006, 27, 2544-2552.	1.0	171
99	Short QT syndrome. Journal of Electrocardiology, 2005, 38, 75-80.	0.4	74
100	Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome. Heart Rhythm, 2005, 2, 254-260.	0.3	180
101	In vitro and in vivo studies on continuous echo-contrast application strategies using SonoVue in a newly developed rotating pump setup. Ultrasound in Medicine and Biology, 2004, 30, 1145-1151.	0.7	19
102	On the design of a capillary flow phantom for the evaluation of ultrasound contrast agents at very low flow velocities. Ultrasound in Medicine and Biology, 2002, 28, 625-634.	0.7	41
103	Feasibility of the flash-replenishment concept in renal tissue: which parameters affect the assessment of the contrast replenishment?. Ultrasound in Medicine and Biology, 2001, 27, 937-944.	0.7	87
104	The impact of emission power on the destruction of echo contrast agents and on the origin of tissue harmonic signals using power pulse-inversion imaging. Ultrasound in Medicine and Biology, 2001, 27, 1525-1533.	0.7	28
105	Blood Flow Assessment by Ultrasound-Induced Destruction of Echocontrast Agents Using Harmonic Power Doppler Imaging: Which Parameters Determine Contrast Replenishment Curves?. Echocardiography, 2001, 18, 1-8.	0.3	31
106	Continuous-Infusion Contrast-enhanced US: In Vitro Studies of Infusion Techniques with Different Contrast Agents. Radiology, 2001, 220, 647-654.	3.6	7
107	Stimulated acoustic emission: pseudo-Doppler shifts seen during the destruction of nonmoving microbubbles. Ultrasound in Medicine and Biology, 2000, 26, 1161-1167.	0.7	58